首页ABVX • EPA
add
Abivax SA
市场资讯
财务信息
损益表
收入
净收入
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 339.30万 | 201.87% |
经营支出 | 4339.10万 | 119.55% |
净收入 | -4081.90万 | -57.14% |
净利润率 | -1203.04 | 47.94% |
每股收益 | — | — |
息税折旧摊销前利润 | -3991.25万 | -114.56% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 2.22亿 | 94.37% |
总资产 | 2.84亿 | 66.29% |
负债总额 | 1.58亿 | 74.43% |
权益总额 | 1.26亿 | — |
发行在外的股份 | 6292.14万 | — |
市净率 | 4.08 | — |
资产回报率 | -35.15% | — |
资本回报率 | -41.69% | — |
现金流
现金净变动
| (EUR) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | -4081.90万 | -57.14% |
来自运营的现金 | -4258.75万 | -208.62% |
投资现金 | 672.90万 | 886.10% |
融资现金 | 2016.10万 | -65.46% |
现金净变动 | -1481.25万 | -133.88% |
自由现金流 | -2107.35万 | -45.88% |
简介
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
CEO
成立时间
2013年12月4日
员工数量
62
